The CHI SQUARE Trial

Jump to navigation Jump to search

High Density Lipoprotein Microchapters

Home

Patient information

Overview

Historical Perspective

Classification

Physiology

Pathophysiology

Causes

Low HDL
High HDL

Epidemiology and Demographics

Screening

Natural History, Complications and Prognosis

Diagnosis

HDL Laboratory Test

Treatment

Medical Therapy

Prevention

Future or Investigational Therapies

Clinical Trials

Landmark Trials

List of All Trials

Case Studies

Case #1

The CHI SQUARE Trial On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of The CHI SQUARE Trial

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on The CHI SQUARE Trial

CDC on The CHI SQUARE Trial

The CHI SQUARE Trial in the news

Blogs on The CHI SQUARE Trial

Directions to Hospitals Treating High density lipoprotein

Risk calculators and risk factors for The CHI SQUARE Trial

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Rim Halaby, M.D. [2]

Official Title

CHI SQUARE: Can HDL Infusions Significantly Quicken Atherosclerosis Regression? A phase II, multi-center, double-blind, ascending dose, placebo-controlled, dose-finding trial of CER-001 or placebo in subjects with acute coronary syndrome.

Objective

To determine the safety and efficacy of CER-001 on atherosclerotic plaque progression and regression in patients with acute coronary syndromes.

Cerenis Therapeutics, SA

Timeline

Timeline
Start Date March 2011
End Date March 2013
Status Complete

The previous information was derived from ClinicalTrials.gov on 09/15/2015 using the identification number NCT01201837.

Study Description

Study Description
Study Type Interventional
Study Phase Phase 2
Study Design
Allocation Randomized
Endpoint Safety/efficacy study
Interventional Model Parallel assignment
Masking Double Blind
Study Details
Primary Purpose Treatment
Condition Acute coronary syndrome
Intervention Drug: placebo (weekly injection)
Drug: CER-001 (weekly injection)
Study Arms Placebo
CER-001 low dose (weekly injection)
CER-001 medium dose (weekly injection)
CER-001 high dose(weekly injection)
Population Size 507 patients

The previous information was derived from ClinicalTrials.gov on 09/15/2015 using the identification number NCT01201837.

Eligibility Criteria

Inclusion Criteria

  • Age < 75 years
  • Patients with ACS
  • Angiographic evidence of CAD with suitable target coronary artery for IVUS evaluation

Exclusion Criteria

  • Female of child bearing potential
  • Weight > 120 kg
  • Angiographic evidence of left main artery stenosis > 50%
  • Uncontrolled diabetes mellitus, defined as HbA1c>10%
  • Triglyceride levels > 500 mg/dL
  • Symptomatic congestive heart failure with NYHA class III or IV or EF<35%
  • Uncontrolled hypertension defined as SBP>180 mmHg
  • Past medical history of renal disease, liver disease, metabolic disease, GI disease, or endocrine dysfunction

Outcomes

Primary Outcomes

The absolute change in total plaque volume as assessed by IVUS from baseline to follow-up at 3 weeks following the final infusion of CER-001 (approximately 9 weeks following baseline measure).

Secondary Outcomes

The percent change in total plaque volume as assessed by IVUS from baseline to follow-up at 3 weeks following the final infusion of CER-001 (approximately 9 weeks following baseline measure).

Publications

  • Primary Results Publication:
Tardif JC, Ballantyne CM, Barter P, et al. Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial. Eur Heart J. 2014;35(46):3277-86.

Results

  • A total of 517 patients were randomized, of which 417 had IVUS and 461 had QCA measurements.
  • Compared with placebo, there was no statistically significant difference in either the nominal or the percent total atheroma volume with any dose of CER-001.
  • The incidence of major cardiovascular events (MACE) was are statistically similar across all treatment groups (8.3% (10), 13.3% (16), and 13.7% (17) in 3 mg/kg, 6 mg/kg, and 12 mg/kg CER-001 groups respectively vs. 9.8% (12) in placebo)

Conclusion

Infusion with CER-001 is not associated with a significant reduction in coronary atherosclerosis as evaluated by IVUS and QCA.

References